Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies.
| Company | Date | Round | Size | Participants |
| PowerVision | 1/12 | Series C | $12.5M | 1 |
| Atlas Genetics | 7/11 | Series B | £16.9M | 5 |
| Spinal Modulation | 6/11 | Series D | $30M | 8 |
| 23andMe | 1/11 | Series C | $9M | 1 |
| Zeo | 1/11 | Series C | $12.3M | 4 |
| Genocea Biosciences | 1/11 | Series B | $35M | 9 |
| Syntaxin | 11/10 | Series C | $29M | 7 |
| Intio | 10/10 | Series B | $8.1M | 1 |
| Aquinox Pharmaceuticals | 6/10 | Series B | $25M | 4 |
| PhaseBio Pharmaceuticals | 1/10 | Series B | $25M | 5 |
| Molecular Partners | 12/09 | Series B | $44.2M | 5 |
| Spinal Modulation | 11/09 | Series C | $27.4M | 7 |
| Celladon | 11/09 | Series C | $21.8M | 3 |
| Sleep Solutions | 10/09 | Series F | $20M | 6 |
| Direct Flow Medical | 10/09 | Series C | $40M | 7 |
| iScience Interventional | 5/09 | Series F | $20.5M | 8 |
| Brainsgate | 8/08 | Venture Round | $27.5M | 1 |
| Neuron Systems | 8/08 | Series A | $8.96M | 2 |
| InSound Medical | 2/08 | Series E | $11M | 3 |
| Syntaxin | 10/07 | Series B | $32M | 5 |
| PhaseBio Pharmaceuticals | 10/07 | Series B | $6.6M | 3 |
| Tengion | 10/07 | Series C | $33M | 9 |
| Biolex Therapeutics | 5/07 | Series C | $30M | 9 |
| Axial Biotech | 3/07 | Series B | $15.3M | 3 |
| Tengion | 6/06 | Series B | $50M | 7 |
| Light Sciences Oncology | 12/05 | Series A | $67M | 8 |
